# Lexaria (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing

* Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2
* The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug
* For Lexaria, the results from this study look to validate earlier studies that have demonstrated improvements in the delivery of semaglutide into the bloodstream
* Results from the GLP-1-H24-2 study are set to be announced in late August or early September

 Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the dosing completion of its human pilot study #2, GLP-1-H24-2. Lexaria’s patented DehydraTECH(TM) “drug delivery platform technology” increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of APIs. The potential of effective oral delivery of GLP -1 drugs, a class of drugs used to address diabetes and weight loss, represents a vast global market potential for DehydraTECH.

 Blood samples collected throughout the study have been transported to the bioanalytical lab for analysis, and the organization looks to complete the analysis and announce the results in late…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

 About CannabisNewsWire

 CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.CannabisNewsWire.com

 Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

 CannabisNewsWireDenver, COwww.CannabisNewsWire.com303.498.7722 OfficeEditor@CannabisNewsWire.com

 CannabisNewsWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ibn-prem/lexaria-nasdaq-lexx-to-validate-earlier-semaglutide-studies-with-successful-glp-1-h24-2-study-dosing/)
                    

[Newsramp.com TLDR](None) 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1f2fjhd/lexaria_bioscience_completes_human_pilot_study/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/248/27/smogjHVL.webp)